GlassScriptPhysician profile
Erica A Taylor
NPI 1457570822
$4,194.92
in general payments reported to CMS, 2019-2025
24 companies · $2,118 in 2025
The $2,118 reported for 2025 was more than what 93% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $248 · 2022: $36.47 · 2023: $290 · 2024: $1,502 · 2025: $2,118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,910.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,910.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,193.78 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $639.72 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $421.32 | 2023-2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $277.24 | 2024-2025 | Qelbree |
| Janssen Pharmaceuticals, INC | $256.35 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Vanda Pharmaceuticals INC. | $251.37 | 2024-2025 | Fanapt, Hetlioz |
| Sunovion Pharmaceuticals INC. | $195.92 | 2021-2022 | |
| Neos Therapeutics, LP | $117.39 | 2023-2025 | Adzenys Xr-Odt |
| Janssen Scientific Affairs, LLC | $102.45 | 2024 | Spravato, Invega Trinza |
| Takeda Pharmaceuticals U.S.A., INC. | $100.47 | 2023-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $96.33 | 2024-2025 | Caplyta |
| Corium, LLC | $80.29 | 2024-2025 | Azstarys |
| Tempus Ai, INC | $60.77 | 2024 | |
| Noven Therapeutics, LLC | $52.73 | 2024-2025 | Xelstrym |
| Almatica Pharma LLC | $50.31 | 2025 | Loreev Xr |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $49.43 | 2024-2025 | Dyanavel Xr |
| Alkermes, INC. | $44.52 | 2021-2025 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $43.19 | 2024-2025 | |
| Lundbeck LLC | $37.14 | 2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $36.70 | 2024 | Uzedy |
| Biogen, INC. | $25.50 | 2025 | Zurzuvae |
| E.R. Squibb & Sons, L.L.C. | $25.49 | 2025 | Cobenfy |
| Vertical Pharmaceuticals, LLC | $22.94 | 2025 | Relexxii |
| Idorsia Pharmaceuticals US INC | $13.57 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erica Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.